Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 06:59 EDT
Citi analyst Yigal Nochomovitz said Acceleron's PULSAR data for sotatercept was "a clear win" in a high risk/high reward trial to which the market had priced in little value prior to the report. He is adding sotatercept to his model with a 70% probability of success, leading him to raise his price target for Acceleron shares to $138 from $75. Nochomovitz remains a buyer of the stock, as he sees additional upside to the market's initial reaction, which has already driven the stock up 65%, he noted. He maintains a Buy rating on Acceleron shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN